BIIB Biogen Inc.

Biogen Announces Webcast of Virtual Annual Meeting of Stockholders

Biogen Inc. (NASDAQ: BIIB) announced today that the webcast of the Company's 2017 Annual Meeting of Stockholders will be held on Wednesday, June 7, 2017 at 9:00 a.m. Eastern Daylight Time. A live audio webcast of the meeting will be available on the Investor Relations section of the Company's corporate website at www.biogen.com/investors or directly via www.virtualshareholdermeeting.com/BIIB. An archive of the webcast will be available for replay following the meeting. Please allow at least 10 minutes prior to the event to visit the site and download the necessary software to listen to the webcast.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

EN
31/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

Laura Chico
  • Laura Chico
 PRESS RELEASE

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Earl...

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance do...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch